William Todd Horich, SVP of Commercial Operations at Supernus Pharmaceuticals, Inc., filed a Form 4 on November 2, 2026, disclosing the acquisition of 100,000 restricted stock units on October 30, 2026.

Key Highlights

  • Reporting person: William Todd Horich, SVP, Commercial Operations at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
  • Grant date: October 30, 2026, for 100,000 restricted stock units (RSUs) at a price of $0
  • Vesting trigger: 40% of RSUs vest upon the closing of a merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc.
  • Remaining vesting schedule: 15% each on the one-, two-, three-, and four-year anniversaries of the merger closing
  • Settlement: RSUs are settled in common stock upon vesting
  • Beneficial ownership following transaction: 100,000 derivative securities, held directly

Supernus SVP Horich Granted Merger-Linked RSUs in October 2026

According to the Form 4 filed with the SEC on November 2, 2026, William Todd Horich, identified as SVP of Commercial Operations at Supernus Pharmaceuticals, Inc., acquired 100,000 restricted stock units on October 30, 2026. The transaction code was reported as "A" (acquired), and the price of the derivative security was listed as $0. Following the transaction, Horich beneficially owns 100,000 RSUs directly, as disclosed in Table II of the filing.

The filing's explanation of responses states that these RSUs are settled in common stock upon vesting and are structured around a specific corporate event. Specifically, 40% of the RSUs vest upon the closing of what the filing describes as "the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc." The remaining 60% vests in four equal installments of 15% each on the one-, two-, three-, and four-year anniversaries of that closing date.

No non-derivative securities transactions were reported in Table I of the filing. The Form 4 was signed by Timothy C. Dec as attorney-in-fact on November 2, 2026, and was filed as an individual, single-reporting-person disclosure. No amendment date was indicated, meaning this appears to be an original filing rather than an amendment to a prior submission.

What Was Disclosed

The filing disclosed that SVP William Todd Horich received a grant of 100,000 RSUs on October 30, 2026, with vesting contingent on the closing of a described merger-of-equals between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and subsequent anniversaries of that closing.